China tests new anti coronavirus drug on patients Xinhua

BEIJING The registration for clinical trials on the antiviral drug ‘Remdesivir’ has been approved as the first batch of patients infected with the 2019 novel coronavirus (2019 nCoV) began to take it on Thursday.

Head of the drug’s clinical trial program Cao Bin said at a press conference that this approval was supported by the Ministry of Science and Technology, the National Health Commission and the National Medical Products Administration, according to Xinhua News Agency.

Remdesivir, developed by the US based pharmaceutical company Gilead Sciences, showed good activity against Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) coronavirus in previous experiments on cells and animals, which will be applied to 761 infected patients, he explained.

Source: Kuwait News Agency